Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 34Terminated 6Unknown 4Withdrawn 1

Sponsor Class

NIH 3FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Breast 1

Conditions

Prostatic Neoplasms 4

Interventions

Docetaxel 33Radiosurgery 23Radiotherapy 21Sunitinib 20pembrolizumab 18Gemcitabine 16Cisplatin 16Androgen Antagonists 15Nivolumab 14enzalutamide 13Goserelin 13Prednisone 12Leuprolide 12Blood Specimen Collection 12Abiraterone Acetate 12bicalutamide 11aldesleukin 11Surveys and Questionnaires 11Cyclophosphamide 11Gonadotropin-Releasing Hormone 10Bevacizumab 10Multiparametric Magnetic Resonance Imaging 9Carboplatin 9acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 8Triptorelin Pamoate 8Radiotherapy, Intensity-Modulated 8Filgrastim 8Epirubicin 8Chemotherapy, Adjuvant 8Brachytherapy 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Estramustine × Genitourinary × Clear all
NCT00002775 2014-01-06

Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
37 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003633 2013-12-19

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Unknown
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003717 2013-12-19

Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
17 enrolled
Genitourinary

Prostatic Neoplasms

NCT00218205 2005-09-22

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

Department of Veterans Affairs, New Jersey

Phase 2 Unknown
28 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡